This is an important time for Polish biotechnology. Despite geopolitical turmoil, many companies are increasingly close to breakthroughs and commercialization of their projects. We believe that the successful registration process of BCX-CM-J for canine osteoarthritis and BCX-EM for equine arthritis will pave the way for further innovations from Poland. Meanwhile, significant biotechnology projects typically originate in the academic world. Without structural changes at the core, primarily in the way such projects are financed, it is difficult to expect that “made in Poland” discoveries will break through the academic walls by Western standards.
Read more: Pesymizm wokół biotechnologii jest absurdalnie wysoki. Fala się odwróci?